Finance
UK court upholds watchdog's finding on excessive NHS thyroid drug prices
Published by Global Banking & Finance Review®
Posted on May 8, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on May 8, 2025
1 min readLast updated: January 24, 2026
The UK Court of Appeal upheld a £99M fine against Advanz Pharma for overcharging the NHS for thyroid drug liothyronine, confirming CMA's finding of excessive pricing.
(Reuters) -The Court of Appeal has upheld a British watchdog's 99 million pound ($131.94 million) fine against owners of Advanz Pharma for overcharging the National Health Service for essential thyroid drug liothyronine, the watchdog said on Thursday.
"In a unanimous judgment, the Court of Appeal has confirmed the Competition and Markets Authority's (CMA) finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK," the CMA said.
($1 = 0.7504 pounds)
(Reporting by DhanushVignesh Babu in Bengaluru; Editing by Arun Koyyur)
The Court of Appeal upheld the Competition and Markets Authority's finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK.
Advanz Pharma was fined 99 million pounds, which is approximately $131.94 million, for overcharging the National Health Service.
The CMA's ruling is significant as it confirms the authority's stance against excessive pricing in essential medicines, impacting healthcare costs in the UK.
Explore more articles in the Finance category
